Skip to main content

Table 2 Acute Toxicity Rates (CTCAE v.5)

From: 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment

Genitourinary (frequency, urgency, pain)

 G2: 3 (12%)

 G1: 6 (24%)

Gastrointestinal (rectal pain)

 G2: 1 (4%)

 G1: 2 (8%)